Yaazh Xenomics
Menu
StoreSign inRequest a quote
Home / Medical Genomics / NIPT — Non-Invasive Prenatal Testing

NIPT — Non-Invasive Prenatal Testing

Safe, non-invasive prenatal screening from maternal blood, analysing cell-free fetal DNA for common trisomies (21, 18, 13) and sex-chromosome aneuploidies from as early as 10 weeks.

What we offer

Trisomy 21, 18 & 13 screening
Sex-chromosome aneuploidy detection
From a single maternal blood draw
High sensitivity & specificity

What you receive

Raw FASTQ data with QC reports
Reference-aligned BAM / CRAM files
Annotated variant calls (VCF)
De novo / hybrid assembly contigs
Coverage & quality metrics dashboard
Publication-ready summary report

Workflow

1

Sample & QC

Extraction, QC and library prep under documented, standardised protocols.

2

Sequencing / Processing

Calibrated runs and pipelines on validated platforms.

3

Bioinformatics

HPC-backed assembly, alignment, variant calling and annotation.

4

Report & Insight

Publication-ready reports, with a dedicated project manager throughout.

Frequently asked

We accept tissue, whole blood, cell pellets, extracted DNA/RNA and a range of environmental and microbial samples. Our team advises on collection and shipping for each project.

Specifications
SampleMaternal blood (10 mL)
From10 weeks gestation
ConditionsT21 / T18 / T13 + SCA
Turnaround7 – 10 days

Get a tailored quote

Tell us your sample type, scope and timelines — we'll respond within one business day.

Request a Quote

Original Page Content

NIPT_Non_Invasive Prenatal_Testing

NIPT – Non-Invasive Prenatal Testing in India | Advanced Fetal Genetic Screening

Yaazh Xenomics offers highly accurate **Non-Invasive Prenatal Testing (NIPT)** in India using state-of-the-art Next-Generation Sequencing (NGS) technology. Our NIPT test analyzes cell-free fetal DNA (cffDNA) circulating in maternal blood to screen for common chromosomal aneuploidies and select microdeletions with exceptional sensitivity and specificity.

What is NIPT (Non-Invasive Prenatal Testing)?

NIPT is a screening test performed as early as 10 weeks of pregnancy. It analyzes fragments of fetal DNA present in the mother’s bloodstream (cell-free fetal DNA) without any risk to the fetus. Unlike invasive procedures such as amniocentesis or CVS, NIPT is completely safe and carries no risk of miscarriage.

Our NIPT Technology & Methodology

Key Features of Yaazh Xenomics NIPT

  • Targeted NGS-based approach with deep sequencing coverage
  • Analysis of chromosomes 13, 18, 21, X, and Y
  • Optional microdeletion screening (22q11.2, 1p36, Angelman/Prader-Willi, Cri-du-chat)
  • Fetal fraction estimation with quality control metrics
  • Advanced bioinformatics pipeline with proprietary algorithms
  • High sensitivity (>99.9% for Trisomy 21) and specificity (>99.9%)

Conditions Screened by Our NIPT Test

Core Aneuploidy Screening

  • Trisomy 21 (Down Syndrome)
  • Trisomy 18 (Edwards Syndrome)
  • Trisomy 13 (Patau Syndrome)
  • Sex Chromosome Aneuploidies (Turner, Klinefelter, Triple X, XYY)

Optional Microdeletion Panel

  • 22q11.2 Deletion Syndrome (DiGeorge/Velocardiofacial syndrome)
  • 1p36 Deletion Syndrome
  • Angelman/Prader-Willi Syndrome (15q11–q13)
  • Cri-du-chat Syndrome (5p deletion)

NIPT Workflow at Yaazh Xenomics

  1. Pre-Test Genetic Counselling – Detailed discussion of test limitations, sensitivity, and clinical implications
  2. Maternal Blood Collection – 10 ml peripheral blood in specialized cfDNA tubes (from 10 weeks gestation)
  3. Cell-Free DNA Extraction & Library Preparation
  4. Targeted Next-Generation Sequencing – Deep sequencing of selected chromosomal regions
  5. Advanced Bioinformatics Analysis – Proprietary algorithms for fetal fraction estimation and aneuploidy detection
  6. Clinical Reporting & Post-Test Counselling – Clear, easy-to-understand report with genetic counsellor support

Clinical Performance

  • Sensitivity for Trisomy 21: >99.9%
  • Specificity for Trisomy 21: >99.9%
  • Positive Predictive Value significantly higher than traditional serum screening
  • Low no-call rate due to robust fetal fraction estimation

Who Should Consider NIPT?

  • All pregnant women (as a primary screening test)
  • Women with advanced maternal age (≥35 years)
  • High-risk pregnancies identified by first-trimester combined screening
  • History of previous chromosomal abnormality
  • Parental balanced translocation carriers

Advantages of NIPT at Yaazh Xenomics

  • Non-invasive – Zero risk to mother or fetus
  • Early detection – From 10 weeks of gestation
  • Higher accuracy than traditional first and second trimester screening
  • Advanced bioinformatics with low false positive rate
  • Fast turnaround time (7–14 working days)
  • Affordable pricing with transparent packages

Yaazh Xenomics Pvt Ltd Module No. 103, TICEL BIOPARK Phase – III, Maruthamalai Road, Coimbatore – 641046, Tamil Nadu, India

Phone: +91 99431 32020 | +91 95002 45454 Email: info@yaazhxenomics.com